Volume 26, Number 9—September 2020
Research Letter
Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
Avnish Sandhu, Glenn Tillotson, Jordan Polistico, Hossein Salimnia, Mara Cranis, Judy Moshos, Lori Cullen, Lavina Jabbo, Lawrence Diebel, and Teena Chopra
Table
Baseline demographic and clinical characteristics of 9 patients with Clostridioides difficile and severe acute respiratory syndrome coronavirus 2 co-infection, Detroit, Michigan, USA, March–April 2020*
| Characteristic | Value |
|---|---|
| Age, y, median |
75 |
| Sex | |
| F | 7 |
| M |
2 |
| Race | |
| African American | 6 |
| Caucasian | 1 |
| Unknown |
2 |
| Hospitalization in prior 60 d | 5 |
| Required intensive care unit and vasopressors |
4 |
| ATLAS score, median† | 6 |
| Charlson comorbidity index score, median |
8 |
| Symptoms at admission | |
| Cough | 4 |
| Shortness of breath | 3 |
| Fever | 4 |
| Diarrhea and abdominal pain |
2 |
| Laboratory results | |
| Ferritin, ng/mL, median‡ | 1,459.4 |
| Leukocyte count, x 103 cells/mm3), average | 12.0 |
| Creatinine, mg/dL, average§ |
4.22 |
| Microbiologic findings | |
| Blood culture positive | 2 |
| Respiratory culture positive | 2 |
*Values indicate no. patients unless otherwise indicated. Some patients had >1 symptom.
†Scoring information available at https://www.mdcalc.com/atlas-score-clostridium-difficile-infection.
‡Ferritin was only obtained in 8 patients.
§Three patients were on dialysis.
Page created: May 20, 2020
Page updated: August 20, 2020
Page reviewed: August 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.